GRI Bio
LA JOLLA, CA · Biotechnology · 9 employees
GRI Bio is a clinical stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells tha
Funding history
- Series seed — $762K — Oct 2024
- Funding Round — $15.6M — Apr 2023
- Funding Round — $15.6M — Apr 2023
- Series seed — $1.3M — Dec 2022
Recent signals
- Oct 25, 2024: Raised $762K in Series seed
- Apr 28, 2023: Raised $15.6M
- Apr 27, 2023: Raised $15.6M
- Dec 22, 2022: Raised $1.3M in Series seed
See plans & pricing → Track GRI Bio’s funding, hiring, and signals — with verified contacts — on Fundz.